Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$74.18−3.48 (-4.48%)
Close on Nov 17, 2026Market cap $1.09BP/E –Yield –
Inhibrx Biosciences cash
Cash and short-term investments held at the end of each period.
Inhibrx Biosciences's cash was $199.47M at Sep 30, 2026. For fiscal 2025 it was $124.22M, down 18.6% from the year before. The highest annual figure on record is $277.92M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $124.22M | -18.6% |
| FY2024 | Dec 31, 2024 | $152.60M | -45.1% |
| FY2023 | Dec 31, 2023 | $277.92M | +1.5% |
| FY2022 | Dec 31, 2022 | $273.87M | +108.6% |
| FY2021 | Dec 31, 2021 | $131.30M | +2.0% |
| FY2020 | Dec 31, 2020 | $128.66M | +1014.9% |
| FY2019 | Dec 31, 2019 | $11.54M | +448.7% |
| FY2018 | Dec 31, 2018 | $2.10M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $199.47M | +30.3% |
| Q2 FY2026 | Jun 30, 2026 | $133.34M | -28.5% |
| Q1 FY2026 | Mar 31, 2026 | $161.66M | -25.3% |
| Q4 FY2025 | Dec 31, 2025 | $124.22M | -18.6% |
| Q3 FY2025 | Sep 30, 2025 | $153.09M | -22.0% |
| Q2 FY2025 | Jun 30, 2025 | $186.57M | -17.8% |
| Q1 FY2025 | Mar 31, 2025 | $216.52M | -14.2% |
| Q4 FY2024 | Dec 31, 2024 | $152.60M | -45.1% |
| Q3 FY2024 | Sep 30, 2024 | $196.33M | -41.8% |
| Q2 FY2024 | Jun 30, 2024 | $226.86M | +17.9% |
| Q1 FY2024 | Mar 31, 2024 | $252.48M | +7.8% |
| Q4 FY2023 | Dec 31, 2023 | $277.92M | +1.5% |
| Q3 FY2023 | Sep 30, 2023 | $337.33M | +130.9% |
| Q2 FY2023 | Jun 30, 2023 | $192.49M | +9.1% |
| Q1 FY2023 | Mar 31, 2023 | $234.25M | +63.3% |
| Q4 FY2022 | Dec 31, 2022 | $273.87M | +108.6% |
| Q3 FY2022 | Sep 30, 2022 | $146.07M | +29.6% |
| Q2 FY2022 | Jun 30, 2022 | $176.39M | +40.3% |
| Q1 FY2022 | Mar 31, 2022 | $143.47M | +32.9% |
| Q4 FY2021 | Dec 31, 2021 | $131.30M | +2.0% |
| Q3 FY2021 | Sep 30, 2021 | $112.70M | -11.7% |
| Q2 FY2021 | Jun 30, 2021 | $125.73M | +2132.4% |
| Q1 FY2021 | Mar 31, 2021 | $107.99M | +25131.3% |
| Q4 FY2020 | Dec 31, 2020 | $128.66M | +1014.9% |
| Q3 FY2020 | Sep 30, 2020 | $127.67M | +426.3% |
| Q2 FY2020 | Jun 30, 2020 | $5.63M | +167.8% |
| Q1 FY2020 | Mar 31, 2020 | $428.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $11.54M | – |
| Q3 FY2019 | Sep 30, 2019 | $24.26M | – |
| Q4 FY2018 | Dec 31, 2018 | $2.10M | – |
See a number that looks wrong?